You are here

Article Text

Article menu
Download PDFPDF
Harm
Cohort study
Inhaled fluticasone and budesonide increased the risk of serious pneumonia in COPD
  1. Patrick White
  1. Department of Primary Care & Public Health Sciences, Kings College London, London, UK
  1. Correspondence to : Dr Patrick White, Primary Care & Public Health Sciences, Kings College London, 9th Floor Capital House, 42 Weston Street, London SE1 3QD, UK; patrick.white{at}kcl.ac.uk

http://dx.doi.org/10.1136/eb-2013-101695

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013;68:1029–36.OpenUrlAbstract/FREE Full Text

    Context

    High-dose inhaled corticosteroids (ICS) reduce the rate of exacerbations in severe and very severe chronic obstructive pulmonary disease (COPD) when prescribed with inhaled long-acting β-agonists (LABA).1 ,2 Although LABA+ICS use is now universally recommended for severe and very severe COPD, the magnitude of their effect is disputed and they are associated with a higher risk of pneumonia.3 Risk of pneumonia has been associated particularly with fluticasone propionate, and less clearly with budesonide.4 ,5 Equivalence of potency between different …

    View Full Text

    Footnotes

    • Competing interests None.